Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

145.44USD
2:29am IST
Change (% chg)

$-0.42 (-0.29%)
Prev Close
$145.86
Open
$146.99
Day's High
$147.94
Day's Low
$145.26
Volume
538,063
Avg. Vol
524,069
52-wk High
$167.70
52-wk Low
$71.50

Chart for

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $39,103.64
Shares Outstanding(Mil.): 252.12
Dividend: --
Yield (%): --

Financials

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA

12 Dec 2017

BRIEF-Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)

* VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS

07 Dec 2017

BRIEF-Vertex receives CHMP positive opinion for Orkambi for the treatment of children with cystic fibrosis ages 6-11

* Vertex receives CHMP positive opinion for Orkambi® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis ages 6-11 with two copies of the f508del mutation in the European Union Source text for Eikon: Further company coverage:

10 Nov 2017

Vertex posts wider net loss, raises cystic fibrosis sales outlook

Oct 25 Vertex Pharmaceuticals Inc reported a wider third-quarter net loss on Wednesday, on higher costs and onetime items, and raised its outlook for full-year sales of its key cystic fibrosis drugs.

26 Oct 2017

BRIEF-Vertex says FDA sets action date of Feb 28, 2018 for its Tezacaftor/Ivacaftor Combination Treatment

* Vertex announces acceptance of its applications for review of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis by the FDA and EMA

24 Aug 2017

BRIEF-FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations

* FDA approves Kalydeco (Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations

01 Aug 2017

BRIEF-Vertex interested in early stage assets consistent with CF focus

* Vertex says interested in acquiring early stage assets in disease areas consistent with cystic fibrosis

27 Jul 2017

UPDATE 1-Vertex Pharma's quarterly profit beats estimates

July 26 Vertex Pharmaceuticals Inc reported a better-than-expected profit for the third straight quarter, helped by improved sales of its cystic fibrosis (CF) drugs.

27 Jul 2017

Vertex Pharma reports quarterly profit

July 26 Vertex Pharmaceuticals Inc reported a quarterly profit, compared with a year-ago loss, helped by higher sales of its cystic fibrosis (CF) drugs.

27 Jul 2017

Wall Street at new highs as tech breaches dot-com era record

NEW YORK The major U.S. stock indexes closed at record highs on Wednesday helped partly by technology stocks, which surpassed a long-standing mark, despite gains on the Dow being capped by a sharp drop in IBM shares. | Video

20 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $141.80 -0.66
Pfizer Inc. (PFE.N) $37.13 -0.07
Novartis AG (NOVN.S) CHF84.10 +0.30
Merck & Co., Inc. (MRK.N) $56.22 -0.02
Roche Holding Ltd. (ROG.S) CHF246.00 +1.90
Roche Holding Ltd. (RO.S) CHF246.80 +3.40
Sanofi SA (SASY.PA) €74.20 +0.65
GlaxoSmithKline plc (GSK.L) 1,304.00 +9.00
AbbVie Inc (ABBV.N) $98.19 +0.74
Bristol-Myers Squibb Co (BMY.N) $62.40 -0.01

Earnings vs. Estimates